The University of Chicago Header Logo

Connection

Kerstin Stenson to Neoplasm Staging

Back to Details
This is a "connection" page, showing publications Kerstin Stenson has written about Neoplasm Staging.
Kerstin Stenson
Connection Strength
0.627
Neoplasm Staging
  1. Neck response to chemoradiotherapy: complete radiographic response correlates with pathologic complete response in locoregionally advanced head and neck cancer. Arch Otolaryngol Head Neck Surg. 2009 Nov; 135(11):1133-6.
    View in: PubMed
    Score: 0.058
  2. Neck dissection planning based on postchemoradiation computed tomography in patients with head and neck cancer. Arch Otolaryngol Head Neck Surg. 2009 Sep; 135(9):876-80.
    View in: PubMed
    Score: 0.058
  3. Efficacy and safety of treating T4 oral cavity tumors with primary chemoradiotherapy. Head Neck. 2009 Aug; 31(8):1013-21.
    View in: PubMed
    Score: 0.057
  4. Planned post-chemoradiation neck dissection: significance of radiation dose. Laryngoscope. 2006 Jan; 116(1):33-6.
    View in: PubMed
    Score: 0.045
  5. Therapeutic options for laryngeal cancer. N Engl J Med. 2003 Nov 27; 349(22):2087-9.
    View in: PubMed
    Score: 0.039
  6. Laryngeal Chondrosarcoma Characteristics and Survival Analysis in the National Cancer Database. Otolaryngol Head Neck Surg. 2022 01; 166(1):101-108.
    View in: PubMed
    Score: 0.032
  7. Occult Lymph Node Metastasis in Early-Stage Glottic Cancer in the National Cancer Database. Laryngoscope. 2021 04; 131(4):E1139-E1146.
    View in: PubMed
    Score: 0.031
  8. The role of cervical lymphadenectomy after aggressive concomitant chemoradiotherapy: the feasibility of selective neck dissection. Arch Otolaryngol Head Neck Surg. 2000 Aug; 126(8):950-6.
    View in: PubMed
    Score: 0.031
  9. Swallowing function in patients with head and neck cancer prior to treatment. Arch Otolaryngol Head Neck Surg. 2000 Mar; 126(3):371-7.
    View in: PubMed
    Score: 0.030
  10. Clinical features and outcomes in young adults with oral tongue cancer. Am J Otolaryngol. 2019 Jan - Feb; 40(1):93-96.
    View in: PubMed
    Score: 0.027
  11. Response-adapted volume de-escalation (RAVD) in locally advanced head and neck cancer. Ann Oncol. 2016 05; 27(5):908-13.
    View in: PubMed
    Score: 0.023
  12. Integrative and comparative genomic analysis of HPV-positive and HPV-negative head and neck squamous cell carcinomas. Clin Cancer Res. 2015 Feb 01; 21(3):632-41.
    View in: PubMed
    Score: 0.020
  13. Lymph node density--prognostic value in head and neck cancer. Head Neck. 2014 Feb; 36(2):266-72.
    View in: PubMed
    Score: 0.019
  14. Outcomes of induction chemotherapy followed by concurrent chemoradiation for nasopharyngeal carcinoma. Oral Oncol. 2013 Mar; 49(3):277-82.
    View in: PubMed
    Score: 0.018
  15. A randomized phase II study of 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy compared with bevacizumab plus 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy for intermediate-stage and T4N0-1 head and neck cancers. Ann Oncol. 2011 Oct; 22(10):2304-9.
    View in: PubMed
    Score: 0.016
  16. Adjuvant chemotherapy prior to postoperative concurrent chemoradiotherapy for locoregionally advanced head and neck cancer. Radiother Oncol. 2010 Nov; 97(2):318-21.
    View in: PubMed
    Score: 0.016
  17. Characteristics associated with swallowing changes after concurrent chemotherapy and radiotherapy in patients with head and neck cancer. Arch Otolaryngol Head Neck Surg. 2008 Oct; 134(10):1060-5.
    View in: PubMed
    Score: 0.014
  18. Induction chemotherapy and concurrent chemoradiotherapy for locoregionally advanced head and neck cancer: a multi-institutional phase II trial investigating three radiotherapy dose levels. Ann Oncol. 2008 Oct; 19(10):1787-94.
    View in: PubMed
    Score: 0.013
  19. Functional organ preservation with definitive chemoradiotherapy for T4 laryngeal squamous cell carcinoma. Ann Oncol. 2008 Sep; 19(9):1650-4.
    View in: PubMed
    Score: 0.013
  20. High survival and organ function rates after primary chemoradiotherapy for intermediate-stage squamous cell carcinoma of the head and neck treated in a multicenter phase II trial. J Clin Oncol. 2006 Jul 20; 24(21):3438-44.
    View in: PubMed
    Score: 0.012
  21. Intensity-modulated radiation therapy in advanced head and neck patients treated with intensive chemoradiotherapy: preliminary experience and future directions. Int J Oncol. 2006 May; 28(5):1141-51.
    View in: PubMed
    Score: 0.011
  22. Phase I study of concomitant chemoradiotherapy with irinotecan, 5-FU, and hydroxyurea for patients with advanced and/or recurrent head and neck cancer. Cancer J. 2005 Mar-Apr; 11(2):140-6.
    View in: PubMed
    Score: 0.011
  23. Neck dissection in the combined-modality therapy of patients with locoregionally advanced head and neck cancer. Head Neck. 2004 May; 26(5):447-55.
    View in: PubMed
    Score: 0.010
  24. Competing causes of death and second primary tumors in patients with locoregionally advanced head and neck cancer treated with chemoradiotherapy. Clin Cancer Res. 2004 Mar 15; 10(6):1956-62.
    View in: PubMed
    Score: 0.010
  25. Concurrent chemoradiotherapy for N2 or N3 squamous cell carcinoma of the head and neck from an occult primary. Ann Oncol. 2003 Aug; 14(8):1306-11.
    View in: PubMed
    Score: 0.009
  26. Radiation therapy with concomitant hydroxyurea and fluorouracil in stage II and III head and neck cancer. J Clin Oncol. 1999 Feb; 17(2):638-44.
    View in: PubMed
    Score: 0.007
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.